Antiangiogenic nanotherapy with lipase-labile Sn-2 fumagillin prodrug.

Pan, Dipanjan; Sanyal, Nibedita; Schmieder, Anne H; Senpan, Angana; Kim, Benjamin; Yang, Xiaoxia; Hu, Grace; Allen, John S; Gross, Richard W; Wickline, Samuel A; Lanza, Gregory M

Pan, Dipanjan; Sanyal, Nibedita; Schmieder, Anne H; Senpan, Angana; Kim, Benjamin; Yang, Xiaoxia; Hu, Grace; Allen, John S; Gross, Richard W; Wickline, Samuel A; Lanza, Gregory M.

Affiliation

Pan D; Division of Cardiology, Washington University School of Medicine, 4320 Forest Park Avenue, Saint Louis, MO 63108, USA. dipanjan@wustl.edu

Nanomedicine (Lond) ; 7(10): 1507-19, 2012 Oct.

Article in En | MEDLINE | ID: mdl-22709347

Subject(s)

Cyclohexanes/therapeutic use; Fatty Acids, Unsaturated/therapeutic use; Lipase/therapeutic use; Nanomedicine; Neovascularization, Pathologic/therapy; Prodrugs/therapeutic use; Animals; Biological Availability; Cells, Cultured; Cyclohexanes/pharmacokinetics; Fatty Acids, Unsaturated/pharmacokinetics; Humans; Mice; Rats; Sesquiterpenes/pharmacokinetics; Sesquiterpenes/therapeutic use

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Therapeutic Methods and Therapies TCIM: Terapias_biologicas / Aromoterapia Main subject: Prodrugs / Cyclohexanes / Nanomedicine / Fatty Acids, Unsaturated / Lipase / Neovascularization, Pathologic Language: En Journal: Nanomedicine (Lond) Year: 2012 Type: Article Affiliation country: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google